BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$278.21 USD
-7.07 (-2.48%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $278.30 +0.09 (0.03%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$278.21 USD
-7.07 (-2.48%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $278.30 +0.09 (0.03%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum D VGM
Zacks News
Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.
Integra's (IART) Q1 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
In CSS, Integra (IART) witnesses a good start to the year with double-digit growth in the CUSA product line and programmable valves as well as strong performance in instrument sales.
Bio-Rad Laboratories (BIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Bio-Rad (BIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Q1 Earnings Top Estimates, '23 View Up
by Zacks Equity Research
Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL Precision system in Europe.
Lamb Weston and TTEC Holdings have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Lamb Weston and TTEC Holdings have been highlighted as Zacks Bull and Bear of the Day.
The Zacks Analyst Blog Highlights BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp
by Zacks Equity Research
BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp are included in this Analyst Blog.
CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) digital capabilities are expected to have driven consumer engagement across all CVS Health businesses in Q1.
Boston Scientific (BSX) Q1 Earnings Beat, 2023 View Raised
by Zacks Equity Research
Reported and organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in the reported quarter.
Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
The year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments drove Thermo Fisher's (TMO) Q1 revenues.
AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal 2023 second-quarter results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
3 MedTech Stocks Likely to Beat Estimates in Q1 Earnings
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.
LabCorp (LH) Q1 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
The decline in COVID-19 PCR and antibody testing sales, the severe foreign exchange headwind and inflationary pressure hurt LabCorp's (LH) business performance in Q1.
Stryker (SYK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) first-quarter results are expected to reflect strong segmental performances. However, rising costs are likely to have continued hurting margins.
Bio-Rad Laboratories (BIO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bio-Rad Laboratories (BIO) closed the most recent trading day at $461.80, moving -1.17% from the previous trading session.
Will Humana's (HUM) Q1 Earnings Beat on Insurance Unit Strength?
by Zacks Equity Research
Humana's (HUM) first-quarter results are likely to reflect surging premiums and investment income.
Can Rising Expenses Hurt Teladoc Health's (TDOC) Q1 Earnings?
by Zacks Equity Research
Teladoc Health's (TDOC) first-quarter results are likely to reflect growth in Access Fees revenues and total visits.
GYN Surgical Sales to Aid Hologic (HOLX) in Q2 Earnings
by Zacks Equity Research
Strong performance led by MyoSure and NovaSure is expected to have driven Hologic' s (HOLX) Q2 performance.
BioRad Laboratories (BIO) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Bio-Rad Laboratories' (BIO) first-quarter 2023 results are likely to reflect an impressive performance across its Life Science segment, with a gradual reduction in backlogs and an improvement in the supply chain.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter results likely to reflect rising volumes across all channels.
What's in Store for West Pharmaceutical (WST) in Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Robust performance from MyoSure and NovaSure along with increasing contributions from the company's laparoscopic portfolio are expected to have contributed to the Hologic's (HOLX) Q2 reveneus.
IDEXX Laboratories (IDXX) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) first-quarter 2023 results are expected to reflect an impressive performance in the CAG segment despite inflationary impacts.
Will Lower Managed Care Profits Hurt Centene's (CNC) Q1 Earnings?
by Zacks Equity Research
Centene's (CNC) first-quarter results are likely to reflect growth in premiums and lower costs.
Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) medical business is expected to have gained from improved U.S. patient traffic to physician offices, ultimate care sites and ambulatory surgical centers.
What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?
by Zacks Equity Research
Continued demand for the HemoSphere monitoring platform and Smart Recovery is likely to have contributed to the Edwards Lifesciences' (EW) Q1 growth.
Baxter (BAX) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.